GC-07. Treatment of oncological diseases with micro-carriers using combined therapy
Alisa S. Postovalova1, Timofey E. Karpov1, Darya R. Akhmetova1, Albert R. Muslimov2, Alexander S. Timin1, Mikhail V. Zyuzin3
1 Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia
2 Pavlov University, St.Petersburg, Russia
3 ITMO University, St. Petersburg, Russia
Dr. Alisa S. Postovalova, phone: +7 (922) 155-83-02, e-mail: firstname.lastname@example.org
Lung cancer is the most common malignant tumor, one of the most frequent causes of cancer-related deaths worldwide and the most common cause of death from oncological pathology. In fact, existing methods of treatment, such as сhemotherapy, radiotherapy and immunotherapy, still are able to evoke side effects in normal tissues when administered alone. That is why it is necessary to improve the effectiveness of lung cancer therapy by developing new approaches. Methods based on the combined use of several approaches of treatment have great potential. Radionuclide and chemotherapy can be considered the most promising methods of treating lung cancer. The aim of this project is to study effectiveness of combined radiotherapy and chemotherapy in lung cancer.
Materials and methods
This study developed a potentially promising treatment with a combination of 177Lu-MPs as polymeric micro-carrier radionuclide, and Cisplatin (a cytostatic for chemotherapy). Balb/c mice with lung metastases received this treatment followed by harvesting and examination of the mice lungs. In the course of experiments, effectiveness of treatment was evaluated by measuring mass of lung tissues and counting the number of metastatic pulmonary nodules in the H&E-stained images calculated by means of Image-Pro Plus.
Histological analysis revealed that the number of metastatic foci in the lungs was significantly decreased. Thus, higher efficiency of the combined therapy was shown, as compared to local radiation therapy with 177Lu-MPs, or Cisplatin chemotherapy.
According to the results of the study, obtained data showed the effectiveness of combined radiotherapy and chemotherapy during in vivo experiments, thus requiring more detailed further studies in the area.
The study was performed with the support of the V. A. Almazov NMHC of the Ministry of Health of the Russian Federation.
Lung cancer, nanobiotechnologies, nanoparticles, combined therapy, micro-carriers.